Antibody ID	ANTI0RYOCW
Antibody Name	IP140B
Synonyms	IP140B    Click to Show/Hide
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)					Antigen Info
Click to Show/Hide the Sequence Information of This Antibody

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 5 nM
Method Description	A Cell line test onNCI-H1975
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 5 nM
Method Description	A Cell line test on OE-33
In Vitro Model	Barrett adenocarcinoma, Adenocarcinoma of the esophagus	OE-33 cells		CVCL_0471

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 5 nM
Method Description	A Cell line test onNCI-H1975
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	< 5 nM
Method Description	A Cell line test on OE-33
In Vitro Model	Barrett adenocarcinoma, Adenocarcinoma of the esophagus	OE-33 cells		CVCL_0471

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5-50 nM
Method Description	A Cell line test on OE-33
In Vitro Model	Barrett adenocarcinoma, Adenocarcinoma of the esophagus	OE-33 cells		CVCL_0471

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5-50 nM
Method Description	A Cell line test on OE-33
In Vitro Model	Barrett adenocarcinoma, Adenocarcinoma of the esophagus	OE-33 cells		CVCL_0471

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5-50 nM
Method Description	A Cell line test on OE-33
In Vitro Model	Barrett adenocarcinoma, Adenocarcinoma of the esophagus	OE-33 cells		CVCL_0471

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5-50 nM
Method Description	A Cell line test on OE-33
In Vitro Model	Barrett adenocarcinoma, Adenocarcinoma of the esophagus	OE-33 cells		CVCL_0471

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5-50 nM
Method Description	A Cell line test on OE-33
In Vitro Model	Barrett adenocarcinoma, Adenocarcinoma of the esophagus	OE-33 cells		CVCL_0471

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	5-50 nM
Method Description	A Cell line test on OE-33
In Vitro Model	Barrett adenocarcinoma, Adenocarcinoma of the esophagus	OE-33 cells		CVCL_0471

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	50-500 nM
Method Description	A Cell line test on OE-33
In Vitro Model	Barrett adenocarcinoma, Adenocarcinoma of the esophagus	OE-33 cells		CVCL_0471

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal inhibitory Concentration (lC50)	50-500 nM
Method Description	A Cell line test on OE-33
In Vitro Model	Barrett adenocarcinoma, Adenocarcinoma of the esophagus	OE-33 cells		CVCL_0471

Ref 1	Antibody-drug conjugates of N-oxacycloalkyl substituted camptothecin derivatives